CIDP Treatment
For chronic inflammatory demyelinating polyneuropathy (CIDP), start with intravenous immunoglobulin (IVIg), corticosteroids, or plasma exchange as first-line therapy, with IVIg or corticosteroids being the most practical initial choices in most clinical settings.
First-Line Treatment Options
The three established first-line therapies for CIDP are equally effective, and your choice should be guided by patient-specific factors 1, 2, 3:
Intravenous Immunoglobulin (IVIg)
- Most commonly used first-line agent in clinical practice
- Effective for both induction and maintenance therapy
- Subcutaneous formulations now available for maintenance 4, 2
- Preferred when rapid response needed or in antibody-mediated subtypes 1
- Key advantage: Better safety profile than corticosteroids, particularly for elderly patients or those with comorbidities
Corticosteroids
- Effective for both induction and maintenance
- Options include daily oral prednisone or pulse methylprednisolone 4
- Key advantage: Lower cost and easier long-term administration
- Major caveat: Significant side effect burden with prolonged use (weight gain, diabetes, osteoporosis, infections)
Plasma Exchange
- Effective as induction therapy 4, 3
- Reserve for: Patients who fail to respond adequately to IVIg or corticosteroids 2
- Key limitation: Requires vascular access, more invasive, typically not used for maintenance
Treatment Algorithm
Initial Treatment Selection
Start with IVIg or corticosteroids based on:
- Patient age and comorbidities (favor IVIg in elderly, diabetics)
- Severity of presentation (consider IVIg for rapid response)
- Local availability and cost considerations
- Suspected antibody-mediated disease (favor IVIg) 1
Evaluate response at 2-4 weeks:
- If adequate response: Continue and reassess at 3-6 months
- If inadequate response: Switch to alternative first-line agent or add plasma exchange 3
Maintenance Therapy
For patients responding to initial treatment 4, 2:
- IVIg maintenance: Repeat infusions (IV or subcutaneous) at intervals determined by individual response
- Corticosteroid maintenance: Taper to lowest effective dose
- Monitor for treatment dependence and attempt dose reduction or withdrawal after sustained improvement 3, 5
Second-Line Options
Consider escalation when first-line therapies fail or as steroid-sparing agents 3, 6:
- Immunosuppressants (azathioprine, mycophenolate, methotrexate)
- Rituximab (particularly effective in antibody-mediated subtypes) 1, 6
- Efgartigimod alfa: FDA-approved FcRn antagonist for refractory CIDP 1
- Novel biologics targeting complement, CD19/20, or neonatal Fc receptors 2, 7
Critical Management Points
Treatment-Related Fluctuations (TRFs)
- Occur in 6-10% of patients 8
- Defined as progression within 2 months after initial improvement
- Management: Repeat full course of IVIg or plasma exchange 8
- Distinguish from: Acute-onset CIDP (≥3 TRFs or deterioration ≥8 weeks after onset) 8
Monitoring Response
- Assess functional improvement (walking ability, grip strength, sensory function)
- Serial nerve conduction studies are helpful but not required for routine monitoring 5
- If no response after adequate trial: Reconsider diagnosis before escalating therapy 5
Common Pitfalls to Avoid
- Misdiagnosis is common - verify diagnostic criteria before committing to long-term immunotherapy 3, 5
- Don't assume treatment failure too early - 40% of patients don't improve in first 4 weeks, but this doesn't mean treatment is ineffective 8
- Recognize atypical variants (distal CIDP, multifocal CIDP, Lewis-Sumner syndrome) - may require different treatment approaches 1, 2
- Antibody-associated forms (anti-neurofascin-155, anti-contactin-1) often respond better to B-cell directed therapy than standard treatments 1, 7